Rohin Gawdi

Mr. Rohin Gawdi

Wake Forest School of Medicine, Winston-Salem NC
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Tithi BiswasTithi Biswas
Tithi Biswas
KKKylie Kang
Kylie Kang
RGRohin Gawdi
Rohin Gawdi
DBDavid L. Bajor
David L. Bajor
MMMitchell Machtay
Mitchell Machtay
Jimmy Thomas EfirdJimmy Thomas Efird
Jimmy Thomas Efird
The Systemic Immune-Inflammation Index (SII) is an important marker of immune function, defined as the product of neutrophil-to-lymphocyte ratio (NLR) and platelet count (P). Higher baseline SII levels have been associated with improved survival in various types of cancers, including lung cancer. Data were obtained from PROCLAIM, a randomized phase III trial comparing two different chemotherapy regimens pemetrexed + cisplatin (PEM) vs. etoposide + cisplatin (ETO), in combination with radiotherapy (RT) for the treatment of stage III non-squamous non-small cell lung cancer (NSCLC). We aimed to determine if SII measured at the mid-treatment window for RT (weeks 3–4) is a significant predictor of survival, and if the effect of PEM vs. ETO differs by quartile (Q) level of SII. Hazard-ratios (HR) for survival were estimated using a proportional hazards model, accounting for the underlying correlated structure of the data. A total of 548 patients were included in our analysis. The median age at baseline was 59 years. Patients were followed for a median of 24 months. Adjusting for age, body mass index, sex, race, and chemotherapy regimen, SII was a significant mid-treatment predictor of both overall (adjusted HR (aHR) = 1.6, p < 0.0001; OS) and progression-free (aHR = 1.3, p = 0.0072; PFS) survival. Among patients with mid-RT SII values above the median (6.8), those receiving PEM (vs. ETO) had superior OS (p = 0.0002) and PFS (p = 0.0002). Our secondary analysis suggests that SII is an informative mid-treatment marker of OS and PFS in locally advanced non-squamous NSCLC.

16 April 2022 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
RGRohin Gawdi
Rohin Gawdi
CVCristian D. Valenzuela
Cristian D. Valenzuela
OMOmeed Moaven
Omeed Moaven
JSJohn A. Stauffer
John A. Stauffer
NPNico R. Del Piccolo
Nico R. Del Piccolo
PSPerry Shen
Perry Shen

28 February 2022 in HPB
Verified
Journal Article
Closed access
CVCristian D. Valenzuela
Cristian D. Valenzuela
OMOmeed Moaven
Omeed Moaven
RGRohin Gawdi
Rohin Gawdi
JSJohn A. Stauffer
John A. Stauffer
NPNico R. Del Piccolo
Nico R. Del Piccolo
PSPerry Shen
Perry Shen

6 April 2026 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
RGRohin Gawdi
Rohin Gawdi
ESElizabeth Nilsson Sjolander
Elizabeth Nilsson Sjolander
JLJoon Sub Lee
Joon Sub Lee
RWRichard L Whelan
Richard L Whelan
Background: The Affordable Care Act expanded Medicaid eligibility to states on staggered timelines, creating a natural experiment to assess health policy effects on colorectal cancer (CRC) outcomes. Methods: We conducted a retrospective quasi-experimental cohort study using the Surveillance, Epidemiology, and End Results database (2006-2019). Patients with CRC <65 years were included in primary analyses; an early-onset colorectal cancer (EOCRC) cohort aged <50 years was examined. States were classified by Medicaid expansion timing, and each expansion group was propensity score-matched against non-expansion controls. The primary analysis used pooled Bayesian difference-in-differences survival models with censoring at 36 months, with sensitivity analyses at 60 months and uncapped follow-up. Secondary Bayesian logistic models evaluated stage at diagnosis and receipt of surgical resection. Results are reported as hazard ratios (HR) or odds ratios (OR) with 95% credible intervals (CrI) and posterior probabilities of benefit. Results: In pooled analyses among patients younger than 65 years, Medicaid expansion was associated with reduced mortality (36-month HR = 0.86; 95% CrI = 0.81-0.92; P[HR < 1]>.999), with consistent findings across follow-up endpoints. Survival benefit was larger among patients with early-onset CRC (age <50 years). No consistent association was observed among Medicare-eligible patients aged ≥65. Medicaid expansion was not associated with population-level shifts in stage at diagnosis or increased surgical resection. Conclusion: Medicaid expansion under the Affordable Care Act was associated with a high probability of improved CRC survival among non–Medicare-eligible adults, including patients with early-onset disease. Survival gains occurred without corresponding changes in stage or surgical treatment, suggesting benefits mediated through improved access, continuity, and delivery of cancer care.

1 December 2025 in JAMA Network Open
Verified
Journal Article
Open access
RGRohin Gawdi
Rohin Gawdi
SIShahidul Islam
Shahidul Islam
CSCalista Sha
Calista Sha
SLShangyi Liu
Shangyi Liu
LGLawrence R. Glassman
Lawrence R. Glassman
PLPaul C. Lee
Paul C. Lee
Importance: Medicaid expansion under the Affordable Care Act broadened eligibility for government-funded health coverage. This may have improved access to early diagnosis and rapid treatment, potentially impacting survival in patients with resectable non–small cell lung cancer (NSCLC), a leading cause of cancer-related death in the US. Objective: To evaluate the association between state-level Medicaid expansion and all-cause mortality in patients with resectable NSCLC. Design, Setting, and Participants: This cohort study of patients aged 20 to 64 years who were diagnosed with stage I to IIIA NSCLC used data from the Surveillance, Epidemiology, and End Results registry collected between January 1, 2006, to December 31, 2019, with outcomes administratively censored at 2 and 4 years. Data were analyzed between March 1 and September 10, 2025. Exposure: Medicaid expansion status of patients’ state of residence at diagnosis. Patients’ states of residence were categorized as nonexpansion, early expansion (2011), 2014 expansion, or late expansion (after 2014). Main Outcomes and Measures: Primary outcomes were 2- and 4-year all-cause mortality. Cox proportional hazards regression models within a difference-in-differences framework were used to estimate adjusted hazard ratios (HRs) for death. Secondary analyses evaluated postexpansion mortality trends and changes in early-stage (I-II) diagnoses using logistic regression. Results: Among 53 842 patients included in the analysis (24 849 [46.2%] 60-64 years of age; 27 027 [50.2%] male), propensity score–matched analyses showed lower 2-year mortality in states with early expansion (HR, 0.95; 95% CI, 0.91-0.99; P = .02) and 2014 expansion (HR, 0.91; 95% CI, 0.86-0.95; P < .001) compared with nonexpansion control states, whereas no significant difference was observed in late expansion states (HR, 0.95; 95% CI, 0.89-1.02; P = .15). All expansion groups showed decreased mortality. Mortality decreases were observed after the first 3 years and persisted throughout the study period. The proportion of early-stage diagnoses did not change post expansion, suggesting benefits may have been mediated by improved postdiagnostic care rather than earlier detection. Conclusions and Relevance: In this cohort study of patients with stage I to IIIA NSCLC, Medicaid expansion was associated with lower mortality at 2 and 4 years. These findings suggest that expanded insurance coverage may have enhanced access to effective cancer care and improved population-level outcomes.

22 January 2026 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
RGRohin Gawdi
Rohin Gawdi
JHJulien T. Hohenleitner
Julien T. Hohenleitner
MWMatthew J. Weiss
Matthew J. Weiss